首页> 外国专利> ENHANCEMENT OF ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)

ENHANCEMENT OF ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)

机译:增强依赖抗体的细胞介导的细胞毒性(ADCC)

摘要

The present invention relates to a method for increasing the therapeutic benefit of an antibody to a subject. The improved benefit is typically mediated by an increase in the antibody-dependent cell-mediated cytotoxicity (ADCC) effect of the antibody. The method comprises (a) administering to said subject an immunotherapeutic composition comprising a component of an immune system checkpoint, or an immunogenic fragment of said component; and (b) also administering said antibody to the subject. The increase in therapeutic benefit to the subject may be in respect of any disease for which the said antibody has a prophylactic or therapeutic effect. The disease may be cancer. The invention also relates to said immunotherapeutic composition and said antibody, and to kits comprising same.
机译:本发明涉及增加抗体对受试者的治疗益处的方法。改善的益处通常由抗体的抗体依赖性细胞介导的细胞毒性(ADCC)作用的增加来介导。该方法包括:(a)给所述受试者施用包含免疫系统检查点的组分或所述组分的免疫原性片段的免疫治疗组合物; (b)还向受试者施用所述抗体。对受试者的治疗益处的增加可以涉及所述抗体对其具有预防或治疗作用的任何疾病。该疾病可能是癌症。本发明还涉及所述免疫治疗组合物和所述抗体,以及涉及包含它们的试剂盒。

著录项

  • 公开/公告号EP3713645A1

    专利类型

  • 公开/公告日2020-09-30

    原文格式PDF

  • 申请/专利权人 IO BIOTECH APS;

    申请/专利号EP20180812101

  • 发明设计人 ANDERSEN MADS HALD;

    申请日2018-11-23

  • 分类号A61P35;A61K39/395;C07K16/28;A61K39;

  • 国家 EP

  • 入库时间 2022-08-21 11:39:55

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号